WebJul 2, 2013 · (xii) Braeburn shall provide advance notice to Titan of any scheduled meetings, and substantive discussions or other communications with the FDA regarding … WebDecember 31, 2024, providing some breathing room for Titan to get Probuphine back on track. 2024 Financial Results For 2024 Titan reported total revenues of $215 thousand increasing from $65 thousand in 2016. Full year research and development costs totaled $9.6 million, rising 57%. The expansion was due to external research and
Titan Pharmaceuticals Schedules Conference Call to Review Fourth ...
Web• Buprenorphine implant (Probuphine®, Braeburn/Titan, FDA approved May 26, 2016) 20 • Buprenorphine subcutaneous extended-release injection (CAM2038, Braeburn, investigational, additional information will be submitted for FDA review) 21. There is interest in understanding whether these new delivery mechanisms might expand access to WebInvestor Conference Call . Scroll Down. Quarterly Results. Annual Reports. Subsidiaries. Investor Day. Corporate Announcements. Other Updates. Stock Information. ... Titan Company Limited Q2 FY'22 Earnings Call - Audio recording . Q2. Titan Company Limited Q3 FY'22 Earnings Call - Audio recording ... building integrity nato
Press Release
WebFeb 1, 2024 · By John Vandermosten, CFA NASDAQ:TTNP Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced on January 22 that it is in discussions with Probuphine … WebTitan to Host Conference Call Today at 4:05pm ET; SOUTH SAN FRANCISCO, CA, USA I December 17, 2012 I Titan Pharmaceuticals, Inc. (OTCBB:TTNP) today announced the signing of a license agreement with Braeburn Pharmaceuticals Sprl, wholly owned by Apple Tree Partners IV, L.P., a partnership affiliated with Apple Tree Partners. The license … WebHighlights of the fourth quarter and full year 2015 will be included in a press release to be issued prior to the call. The live webcast of the call may be accessed by visiting the … crownhill topsoil \\u0026 aggregates